Background {#Sec1}
==========

Network meta-analysis (NMA) (also referred to as mixed treatment comparisons or multiple treatment comparisons) is the quantitative component of a review that combines direct and indirect evidence across a network of treatments \[[@CR1]\]. NMA has many potential benefits compared with pairwise meta-analysis, with one particular advantage being the ability to rank a set of competing treatments according to their safety or effectiveness, or both, thus facilitating clinical decision-making \[[@CR2]\]. The use of NMA methods has become increasingly common \[[@CR3]\], alongside methodological developments (see, for example, Efthimiou et al. \[[@CR4]\] for a recent review of NMA methodology), tutorial papers explaining the methods (e.g. \[[@CR5], [@CR6]\]), and user written packages/routines in Stata, R, and WinBUGS/OpenBUGS (e.g. \[[@CR4], [@CR7]\]).

Two broad approaches have been proposed for the synthesis of evidence across networks. In the first approach, the trial-specific relative treatment effects (e.g. log of the odds ratio) over the trials are pooled (henceforth referred to as contrast-synthesis models), whereas in the second approach, the absolute estimates (e.g. log odds) of each arm are pooled and treatment effects (e.g. odds ratios, risk differences) are constructed from the arm estimates (henceforth referred to as arm-synthesis models) \[[@CR8]\]. Detailed explanations of these models have been published \[[@CR2], [@CR8]--[@CR11]\] and brief explanations are provided below. There has been recent debate about the validity of the arm-synthesis models \[[@CR8], [@CR10], [@CR12]\]; proponents argue that they offer an advantage to standard methods because they allow the analyst to estimate both relative and absolute measures \[[@CR13]\]. However, opponents argue that these methods represent a departure from standard meta-analysis practice as they compromise the advantage of randomisation by relating arms across studies \[[@CR8]\].

A common assumption that is made under the random-effects contrast-synthesis model is that the between-trial heterogeneity variance of the relative treatment effects is the same for every treatment comparison \[[@CR2], [@CR4]\]. This assumption, referred to as the 'homogeneous variance assumption' \[[@CR14]\] reduces the number of parameters that need to be estimated, simplifies the estimation and increases the precision for estimating the heterogeneity variance \[[@CR4]\]. However, even with this assumption, the available data in the network may be limited for estimating the heterogeneity variance. The Bayesian framework for fitting the contrast-synthesis model offers the opportunity of incorporating external estimates of heterogeneity, such as those estimated from large empirical data sets, which may improve precision in the estimation of the heterogeneity variance \[[@CR15]\]. Turner et al. \[[@CR16]\] provide informative prior distributions defined by outcome type and intervention comparison \[[@CR16], [@CR17]\].

Evidence about the relative merits and drawbacks of statistical methods comes from statistical theory, numerical simulation studies, and empirical evaluation. Simulation studies allow investigation of the performance of statistical methods against a known truth \[[@CR18]\], and are useful for exploring the properties of the methods (e.g. Song et al. \[[@CR19]\]), particularly in scenarios where the assumptions of the underlying methods may not be met. Empirical studies allow investigation of how methods work in practice using actual data (e.g. Langan et al. \[[@CR20]\]), and in particular, allow estimation of the magnitude of discordance in results between the methods, and exploration of factors that might predict this discordance. To facilitate both simulation studies and empirical research on NMA methods, a dataset of 456 NMAs containing available data from all published NMAs since 1999 has been compiled \[[@CR21]\].

To our knowledge, no study has empirically compared the results of NMA between the contrast-synthesis and arm-synthesis models across a large number of networks. In this study, we will achieve this through the re-analysis of published networks of interventions with binary outcomes using five NMA models.

Methods/design {#Sec2}
==============

Database of networks {#Sec3}
--------------------

We will use a database of 456 published NMAs of randomised trials that have been previously identified and curated. Details of the methods for locating the NMA publications, inclusion criteria, and the screening process are outlined in Petropoulou et al. \[[@CR21]\]. The database compares networks with at least four different interventions that employed an appropriate synthesis method. The data extracted from the networks (of importance for the present study) included publication characteristics (e.g. year of publication, journal of publication); summary statistics (e.g. number of events and number of participants per arm) from the direct comparisons of the primary NMA outcome in the review (or the outcome identified from a decision tree when no primary outcome was specified \[[@CR21]\]; classification of the outcome in terms of whether it was harmful or beneficial, and whether it was an objective, semi-objective, or subjective measure; and whether the type of included treatment comparisons were pharmacological vs placebo, pharmacological vs pharmacological or non-pharmacological vs any intervention.

Eligibility criteria for the present study {#Sec4}
------------------------------------------

We will include a subset of networks from the database which meet the following inclusion criteria: (i) a binary primary outcome, (ii) the number of events and number of participants are available for each trial arm, and (iii) for networks including at least one closed loop, there is no evidence of statistical inconsistency as detected by a *p* value \<0.10 via the design by treatment interaction test using Stata's **mvmeta** command \[[@CR22]\]. Tests for the evaluation of the consistency of a network, for example, the design by treatment interaction, are known to have low power, which led us to choose a *p* value of 0.10 as our cut-off \[[@CR19], [@CR23]\].

Statistical methods to analyse the networks {#Sec5}
-------------------------------------------

We will begin by describing the notation, then describe the contrast-synthesis models, followed by a brief description of the arm-synthesis models. Details about the estimation methods and packages used to fit the models in R are described in the section '[Implementing the models in R](#Sec8){ref-type="sec"}' below.

In the following, we assume that there are *I* studies in the network (labelled *i* = 1, 2, ..., *I*) and that each study investigates a subset of the *K* treatments. The studies are labelled *k* = 1, 2, ..., *K* and the subset of treatments compared in study *i* is denoted *S* ~*i*~. We further assume that in study *i*, the observed number of events, *y* ~*ik*~, has arisen from a binomial process, *y* ~*ik*~  *\~* bin(*n* ~*ik*~ *,p* ~*ik*~), where *n* ~*ik*~ is the number of participants in arm *k* $\documentclass[12pt]{minimal}
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                \begin{document}$$ \left( k\in {S}_i\right) $$\end{document}$, and *p* ~*ik*~ is the probability of the event.

### Contrast-synthesis models {#Sec6}
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                \begin{document}$$ g\left(\bullet \right) $$\end{document}$ is the logit link, *μ* ~*i*~ are the study-specific baseline effects and will be treated as unrelated nuisance parameters, *δ* ~*ibk*~ represents the study-specific effect of treatment *k* relative to the baseline *b* and *X* ~*ik*~ is an indicator variable which is set to 0 if *k* = *b* and 1 otherwise. The study-specific treatment effects *δ* ~*ibk*~ are drawn from a common random-effects distribution, where *θ* ~*bk*~ represents the mean effect of treatment *k*, relative to the baseline treatment, and *τ* ^*2*^ ~*bk*~ represents the between-trial variance in treatment effects. Finally, we make the consistency assumption that if any two treatments, say *x* and *y*, are compared indirectly through *b*, the result will be consistent with the direct comparison; that is: *θ* ~*xy*~  *= θ* ~*bx*~  *− θ* ~*by*~. For multi-arm trials, an adjustment is required where *δ* ~*ibk*~ is assumed to be multivariate normally distributed \[[@CR2]\]. Implementation of models with a binomial likelihood is possible in either a frequentist or Bayesian framework but these are easier to estimate in a Bayesian framework \[[@CR2]\]. For this reason, we will use a Bayesian framework to fit the variants of this model (see the section '[Contrast-synthesis models in a Bayesian framework](#Sec9){ref-type="sec"}').

An alternative contrast-synthesis approach is to model the estimates of the treatment contrasts. First, let $\documentclass[12pt]{minimal}
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                \begin{document}$$ {\delta}_{ibk} $$\end{document}$ is drawn from the common random-effects distribution above. We will implement this model in a frequentist framework (see section '[Contrast-synthesis model in a frequentist framework](#Sec9){ref-type="sec"}').

### Arm-synthesis models {#Sec7}

The arm-synthesis model is specified such that:$$\documentclass[12pt]{minimal}
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                \begin{document}$$ \varPhi \left(\bullet \right) $$\end{document}$ is the standard normal cumulative distribution function. The log link function can also be used \[[@CR10]\]. The *μ* ~*k*~' s are fixed effects for the treatments, and the random effects $\documentclass[12pt]{minimal}
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                \begin{document}$$ {\boldsymbol{\varSigma}}_{\boldsymbol{K}} $$\end{document}$. Various assumptions can be made about the variance-covariance matrix, which allow for different correlations across the studies. Consistency on the probit scale is implicit in this model. For further details of this model, the reader is referred to Zhang et al. \[[@CR13], [@CR24]\]. We will implement this model in a Bayesian framework (see the section 'Arm-synthesis models in a Bayesian framework').

Implementing the models in R {#Sec8}
----------------------------

### Contrast-synthesis models in a Bayesian framework {#Sec9}

We will fit two contrast-synthesis models in a Bayesian framework using the R package **gemtc** <https://cran.r-project.org/package=gemtc> (Table [1](#Tab1){ref-type="table"}). For both models, we will fit a random-effects consistency model, with a binomial likelihood and logit link function, and a variance-scaling factor of 2.5. We will use two different prior distributions for the between-trial heterogeneity standard deviation (*τ*): a vague prior uniform distribution, where $\documentclass[12pt]{minimal}
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                \begin{document}$$ \tau \sim \mathrm{Uniform}\left(0,10\right) $$\end{document}$ \[[@CR25]\] (referred to as contrast-synthesis model 1) and an informative prior distribution (referred to as contrast-synthesis model 2). The informative prior distribution will be selected from the predictive distributions for between-trial variance available in Turner et al \[[@CR16]\]. These distributions are specific to outcome types (all-cause mortality, subjective, semi-objective) and treatment comparisons (pharmacological, non-pharmacological, placebo/control). Our networks have been classified using the same categorisation as in Turner et al. \[[@CR16]\]. Specifically, in the presence of placebo in the network, the network was categorised as pharmacological vs placebo. If only pharmacological treatments were available, then the network was categorised as pharmacological vs pharmacological, whereas if a non-pharmacological treatment was included in the network, then the network was categorised as non-pharmacological vs any category. For the contrast-synthesis models 1 and 2, we will assume a common estimate for the between-trial heterogeneity variance across the different treatment comparisons \[[@CR11]\].Table 1Overview of the methods applied to synthesise the evidence from network meta-analysesMethod labelPackage used in RContrast-level or arm-level input dataFrequentist or Bayesian frameworkLikelihood and link functionsHeterogeneityPrior distributionsTreatment-specific fixed effectsMean effect of treatment k relative to baselineHeterogeneity or random effects parameterContrast-synthesis model 1gemtc (version 0.8.1)Arm-levelBayesianBinomial likelihood and logit linkHomogeneous/commonN/A*δ* ~*k*~ \~ *N*(0, (15\*5)^2^)^a^*τ* ~*bk*~ \~ *U*(0,10)^b^Contrast-synthesis model 2gemtc (version 0.8.1)Arm-levelBayesianBinomial likelihood and logit linkHomogeneous/commonN/A*δ* ~*k*~ \~ *N*(0, (15\*5)^2^)^a^Informative^c^Contrast-synthesis model 3netmeta (version 0.9-2)Contrast-levelFrequentistN/AHomogeneous/commonN/AN/AN/AArm-synthesis model 1^d^pcnetmeta (version 2.4)Arm-levelBayesianBinomial likelihood and probit linkHomogeneous/common*μ* ~*k*~ \~ *N*(0, 1000)N/A*σ* ~*k*~ \~ U(0,10)Arm-synthesis model 2^e^pcnetmeta (version 2.4)Arm-levelBayesianBinomial likelihood and probit linkHeterogeneous*μ* ~k~ \~ *N*(0, 1000)N/A*σ* ~k~ \~ U(0,10)*N/A* not applicable^a^Source: documentation for gemtc package <https://cran.r-project.org/package=gemtc>^b^ *τ* ~bk~ represents the between-trial heterogeneity standard deviation in treatment effects^c^Each network was categorised according to the type of its included treatment comparisons and outcomes \[[@CR21]\]. Specifically, in the presence of placebo in the network, the network was categorised as pharmacological vs placebo. If only pharmacological treatments were available, then the network was categorised as pharmacological vs pharmacological, whereas if a non-pharmacological treatment was included in the network, then the network was categorised as non-pharmacological vs any category. Outcomes were categorised as all-cause mortality, subjective, or semi-objective. The predictive distributions for between-trial heterogeneity variance for each of the treatment comparison by outcome type categories, estimated in Turner et al. \[[@CR16]\], were used as informative priors^d^Model assumes homogeneity of the variances (i.e. common variance) of the random effects and assumes that the off-diagonal elements of the correlation matrix are equal (specified by the hom_eqcor option)^e^Model assumes an unstructured covariance matrix of the random effects and assumes that the off-diagonal elements of the correlation matrix are equal (specified by the het_eqcor option)

### Contrast-synthesis model in a frequentist framework {#Sec10}

We will fit a contrast-synthesis model in a frequentist framework using the R package **netmeta** <https://cran.r-project.org/package=netmeta> (Table [1](#Tab1){ref-type="table"}). The approach implemented in this package is based on weighted least squares estimation. The approach was first developed using graph-theoretical methods that derive from electrical network theory. For a detailed description of the method and its derivation from graph-theoretical methods, the reader is referred to Rücker \[[@CR26]\] and Chapter 8 of Schwarzer et al.'s textbook *Meta-analysis with R* \[[@CR27]\]. We refer to this model as contrast-synthesis model 3. The data will be input as contrast-level data, and the **pairwise** function in the **netmeta** package will be used to convert arm-level data to contrast-level data.

### Arm-synthesis models in a Bayesian framework {#Sec11}

We will fit two arm-synthesis models in a Bayesian framework using the R package **pcnetmeta** [https://CRAN.R-project.org/package=pcnetmeta](https://cran.r-project.org/package=pcnetmeta) (Table [1](#Tab1){ref-type="table"}). For both models, the correlations between the random-effects within studies are assumed equal. We will fit a model with homogeneity of variances of the random-effects (referred to as arm-synthesis model 1), which is implemented by setting the model argument of **pcnetmeta** equal to **hom_eqcor**. Next, we will fit a model with an unstructured heterogeneous variance of the random-effects (referred to as arm-synthesis model 2), which is implemented by setting the model argument of **pcnetmeta** equal to **het_eqcor**. We will use a uniform prior distribution for the standard deviations ($\documentclass[12pt]{minimal}
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                \begin{document}$$ \sigma \sim U n i f o r m\left(0,10\right) $$\end{document}$.

For the Bayesian models (i.e. contrast-synthesis models 1 and 2 and arm-synthesis models 1 and 2), three chains will be used with a burn-in of 300,000 followed by 300,000 samples saved at an interval of 10 from each of the three chains \[[@CR28]\]. Convergence will be assessed by the Brooks--Gelman--Rubin method \[[@CR29], [@CR30]\] and by visual inspection of the history plots \[[@CR31]\].

Network estimates {#Sec12}
-----------------

Analysing each NMA using the five methods described above (contrast-synthesis models 1--3 and arm-synthesis models 1--2), we will estimate the log of the odds ratios and their corresponding standard errors for each pairwise comparison within a network; the rank of each treatment based on the surface under the cumulative ranking (SUCRA) curve \[[@CR31]\]; the corresponding SUCRA value (the *p*-score for the contrast-synthesis model in a frequentist framework); and the between-trial heterogeneity variance for the contrast-synthesis models.

Differences in the network estimates between the methods {#Sec13}
--------------------------------------------------------

We will use the following metrics to compare the network estimates (described in the '[Network estimates](#Sec12){ref-type="sec"}' section) between the five methods:Raw difference in the log of the odds ratioRatio of standard errors of the log of the odds ratiosDifference in rank based on the SUCRA valueDifference in SUCRA valueRatio of the estimates of the between-trial heterogeneity variance for the contrast-synthesis methods.

Exploring factors that might affect the differences in network estimates between the methods {#Sec14}
--------------------------------------------------------------------------------------------

The differences in the estimates between the NMA methods might be modified by several factors including the size of the network, the rareness of events, and the distribution of information in the network. The size of a network and the distribution of information within a network might be determined by the number of studies, the number of treatments, or the number of nodes/comparisons, and their ratios. Therefore, we will investigate whether the following three metrics modify the differences in the network estimates: the ratio of the number of treatments to the number of studies, the ratio of the number of treatments to the number of available direct comparisons, and the ratio of the number of studies to the number of available direct comparisons. We will also investigate if the proportion of arms in a network with less than 10 events modifies differences in the network estimates.

Statistical analysis {#Sec15}
--------------------

We will begin by visually inspecting the effect estimates and confidence/credible intervals for each pairwise comparison within each network (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Log of the odds ratio and corresponding 95% confidence/credible interval for each pairwise comparison within one network. Note that the data pictured is from a network that is not included or related to the networks in our

We will fit multilevel models, including random effects for network and comparison to estimate differences in the metrics (e.g. log(ORs), ranks) between the methods. The initial model will include only a term for method, and additional models will include factors hypothesised to modify differences in the network estimates between the methods. We will use the contrast-synthesis model 1 as the reference method.

Graphical methods {#Sec16}
-----------------

We will present graphical displays of the data that compare network estimates between the methods (described following). For illustrative purposes, Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, and [4](#Fig4){ref-type="fig"} depict results from simulated data, which were not derived from or related to the networks included in our empirical analysis.Fig. 2Bland-Altman plots for the level of agreement between the log of the odds ratios (*top right*) and standard errors for the log of the odds ratios (*bottom left*) comparing the five methods used to synthesise evidence from network meta-analyses. Note that the data pictured have been simulated for illustrative purposes Fig. 3Comparison of ranks (*top right*) and Bland-Altman plots for the level of agreement between the SUCRA values (*bottom left*) obtained from the five methods used to synthesise evidence from network meta-analyses. Note that the data pictured have been simulated for illustrative purposes Fig. 4Comparison of rankings obtained from the five methods used to synthesise evidence from network meta-analyses. Note that the data pictured have been simulated for illustrative purposes

We will graph the log of the odds ratios and 95% confidence/credible interval estimated from each method for each comparison within each of the networks. Figure [1](#Fig1){ref-type="fig"} displays an example from a network that is not included in our cohort. Bland-Altman plots (Fig. [2](#Fig2){ref-type="fig"}) will be presented to assess the agreement between the estimates of the log of the odds ratios (upper corner of Fig. [2](#Fig2){ref-type="fig"}) and standard errors of the log of the odds ratios (lower corner of Fig. [2](#Fig2){ref-type="fig"}) using the five methods. If there is good agreement between methods, we would expect to see the differences between the methods scattered around the line of no difference (i.e., *y*-axis = 0), and most of the differences lying within two standard deviations of the mean difference \[[@CR32], [@CR33]\]. We will also use Bland-Altman plots to assess the agreement between SUCRA estimates (e.g. lower corner of Fig. [3](#Fig3){ref-type="fig"}).

To compare ranks, we will graphically display the agreement between the ranks obtained from each method as a proportion of the total number of treatments for each rank (Fig. [4](#Fig4){ref-type="fig"} and upper corner of Fig. [3](#Fig3){ref-type="fig"}). For example, the first row, second column of the upper corner of Fig. [4](#Fig4){ref-type="fig"}, shows the comparison of ranks between the contrast-synthesis models 1 and 2. The bars in the diagonal show the proportion of times the first and second methods yielded the same result. In the off-diagonal, the proportion of times the first method ranked a treatment as *x* and the second method ranked that same treatment as *y* is displayed (where *x* = 1, 2, ..., 20, and *y* = 1, 2, ..., 20, but *x*  $\documentclass[12pt]{minimal}
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                \begin{document}$$ \ne $$\end{document}$  *y*). In the lower corner of Fig. [4](#Fig4){ref-type="fig"}, we show the proportion of agreement between the methods for the first three rankings (i.e. *x* = 1, 2, and 3). These plots will provide a visual impression of the degree of agreement between the ranks estimated from each method, with greater spread and colour variation indicating less agreement. For example, in Fig. [4](#Fig4){ref-type="fig"}, first row, second column, the dominance of green bars with little variation indicates good agreement in the rankings between contrast-synthesis models 1 and 2, as compared with the first row, fourth column, where there is a lot of spread and colour variation, indicating a lack of agreement in the rankings between contrast-synthesis model 1 and arm-synthesis model 1.

The plots will be created overall and using different shades to identify the network characteristics defined above.

Discussion {#Sec17}
==========

To our knowledge, this will be the first empirical study to compare a range of NMA methods applied to a large number of networks with binary outcomes. We aim to examine how the contrast-synthesis and arm-synthesis models compare; how the contrast-synthesis models in a frequentist and Bayesian framework compare; and how the results of the contrast-synthesis (Bayesian) models might be affected when assuming different prior distributions for the between-trial heterogeneity variance.

There are several strengths of our study. We are using a large number of networks to compare the methods. Therefore, we will be able to conclude with reasonable confidence whether in practice the choice of NMA method matters (for those methods evaluated). Further, following the lead of others \[[@CR34], [@CR35]\], we are publishing a protocol of our methodological study with the aim of clearly reporting and pre-specifying the objectives, design, and methods.

However, our study is not without limitations. We will focus on NMA with binary outcomes, so our findings may not be generalisable to other outcome types, such as continuous outcomes. While we are examining five models, many other models could be fitted, for example, a contrast-synthesis model with random study main effects or a contrast- or arm-synthesis model with unequal correlations between the random effects. Further, in our evaluation of the contrast-synthesis model in a Bayesian framework, we will use the between-trial heterogeneity variance priors from Turner et al. \[[@CR16]\]. For a particular network, there may be a set of available priors (e.g. networks including pharmacological and non-pharmacological interventions) and we will select the prior that has the largest between-trial heterogeneity variance. We have chosen this approach because it is conservative, but other choices may impact on the findings. We are not aware of a set of prior values based on empirical evidence that can be used to vary the prior on the common heterogeneity variance in the arm-synthesis models, so we have limited our investigation of the arm-synthesis models to ones where the prior is fixed. Finally, we will limit the dataset to networks that demonstrate consistency. Although this consistency requirement will reduce the number of included networks, networks with identified inconsistency add to the complexity of the synthesis and are beyond the scope of this empirical study \[[@CR4]\].

The use of NMA to synthesise direct and indirect evidence across a network of treatments is becoming increasingly popular because of the ability to address the important question of which treatment, from a set of treatments, is most effective. However, there is ongoing debate as to the most appropriate method to analyse these networks. This research will provide evidence on whether the choice of method in practice is important and may usefully inform the design of future simulation studies to investigate the performance of NMA methods.
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